Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts

Alex W. Cohen, David S. Park, Scott E. Woodman, Terrence M. Williams, Madhulika Chandra, Jamshid Shirani, Andrea Pereira De Souza, Richard N. Kitsis, Robert G. Russell, Louis M. Weiss, Baiyu Tang, Linda A. Jelicks, Stephen M. Factor, Vitaliy Shtutin, Herbert B. Tanowitz, Michael P. Lisanti

Research output: Contribution to journalArticle

187 Citations (Scopus)

Abstract

Recently, development of a caveolin-1-deficient (Cav-1 null) mouse model has allowed the detailed analysis of caveolin-1's function in the context of a whole animal. Interestingly, we now report that the hearts of Cav-1 null mice are markedly abnormal, despite the fact that caveolin-1 is not expressed in cardiac myocytes. However, caveolin-1 is abundantly expressed in the nonmyocytic cells of the heart, i.e., cardiac fibroblasts and endothelia. Quantitative imaging studies of Cav-1 null hearts demonstrate a significantly enlarged right ventricular cavity and a thickened left ventricular wall with decreased systolic function. Histological analysis reveals myocyte hypertrophy with interstitial/perivascular fibrosis. Because caveolin-1 is thought to act as a negative regulator of the p42/44 MAP kinase cascade, we performed Western blot analysis with phosphospecific antibodies that only recognize activated ERK1/2. As predicted, the p42/44 MAP kinase cascade is hyperactivated in Cav-1 null heart tissue (i.e., interstitial fibrotic lesions) and isolated cardiac fibroblasts. In addition, endothelial and inducible nitric oxide synthase levels are dramatically upregulated. Thus loss of caveolin-1 expression drives p42/44 MAP kinase activation and cardiac hypertrophy.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Cell Physiology
Volume284
Issue number2 53-2
StatePublished - Feb 1 2003

Fingerprint

Caveolin 1
Mitogen-Activated Protein Kinase 1
Cardiomegaly
Fibroblasts
Phosphotransferases
MAP Kinase Signaling System
Phospho-Specific Antibodies
Nitric Oxide Synthase Type III
Nitric Oxide Synthase Type II
Cardiac Myocytes
Muscle Cells
Hypertrophy
Endothelium
Animals
Fibrosis
Western Blotting
Chemical activation
Tissue
Imaging techniques

Keywords

  • Cardiac fibroblasts
  • Cardiomyopathy
  • Caveolae
  • Signal transduction

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Cohen, A. W., Park, D. S., Woodman, S. E., Williams, T. M., Chandra, M., Shirani, J., ... Lisanti, M. P. (2003). Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. American Journal of Physiology - Cell Physiology, 284(2 53-2).

Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. / Cohen, Alex W.; Park, David S.; Woodman, Scott E.; Williams, Terrence M.; Chandra, Madhulika; Shirani, Jamshid; De Souza, Andrea Pereira; Kitsis, Richard N.; Russell, Robert G.; Weiss, Louis M.; Tang, Baiyu; Jelicks, Linda A.; Factor, Stephen M.; Shtutin, Vitaliy; Tanowitz, Herbert B.; Lisanti, Michael P.

In: American Journal of Physiology - Cell Physiology, Vol. 284, No. 2 53-2, 01.02.2003.

Research output: Contribution to journalArticle

Cohen, AW, Park, DS, Woodman, SE, Williams, TM, Chandra, M, Shirani, J, De Souza, AP, Kitsis, RN, Russell, RG, Weiss, LM, Tang, B, Jelicks, LA, Factor, SM, Shtutin, V, Tanowitz, HB & Lisanti, MP 2003, 'Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts', American Journal of Physiology - Cell Physiology, vol. 284, no. 2 53-2.
Cohen, Alex W. ; Park, David S. ; Woodman, Scott E. ; Williams, Terrence M. ; Chandra, Madhulika ; Shirani, Jamshid ; De Souza, Andrea Pereira ; Kitsis, Richard N. ; Russell, Robert G. ; Weiss, Louis M. ; Tang, Baiyu ; Jelicks, Linda A. ; Factor, Stephen M. ; Shtutin, Vitaliy ; Tanowitz, Herbert B. ; Lisanti, Michael P. / Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. In: American Journal of Physiology - Cell Physiology. 2003 ; Vol. 284, No. 2 53-2.
@article{5fc1ab1d9be34ed6b474d02a732d54be,
title = "Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts",
abstract = "Recently, development of a caveolin-1-deficient (Cav-1 null) mouse model has allowed the detailed analysis of caveolin-1's function in the context of a whole animal. Interestingly, we now report that the hearts of Cav-1 null mice are markedly abnormal, despite the fact that caveolin-1 is not expressed in cardiac myocytes. However, caveolin-1 is abundantly expressed in the nonmyocytic cells of the heart, i.e., cardiac fibroblasts and endothelia. Quantitative imaging studies of Cav-1 null hearts demonstrate a significantly enlarged right ventricular cavity and a thickened left ventricular wall with decreased systolic function. Histological analysis reveals myocyte hypertrophy with interstitial/perivascular fibrosis. Because caveolin-1 is thought to act as a negative regulator of the p42/44 MAP kinase cascade, we performed Western blot analysis with phosphospecific antibodies that only recognize activated ERK1/2. As predicted, the p42/44 MAP kinase cascade is hyperactivated in Cav-1 null heart tissue (i.e., interstitial fibrotic lesions) and isolated cardiac fibroblasts. In addition, endothelial and inducible nitric oxide synthase levels are dramatically upregulated. Thus loss of caveolin-1 expression drives p42/44 MAP kinase activation and cardiac hypertrophy.",
keywords = "Cardiac fibroblasts, Cardiomyopathy, Caveolae, Signal transduction",
author = "Cohen, {Alex W.} and Park, {David S.} and Woodman, {Scott E.} and Williams, {Terrence M.} and Madhulika Chandra and Jamshid Shirani and {De Souza}, {Andrea Pereira} and Kitsis, {Richard N.} and Russell, {Robert G.} and Weiss, {Louis M.} and Baiyu Tang and Jelicks, {Linda A.} and Factor, {Stephen M.} and Vitaliy Shtutin and Tanowitz, {Herbert B.} and Lisanti, {Michael P.}",
year = "2003",
month = "2",
day = "1",
language = "English (US)",
volume = "284",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2 53-2",

}

TY - JOUR

T1 - Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts

AU - Cohen, Alex W.

AU - Park, David S.

AU - Woodman, Scott E.

AU - Williams, Terrence M.

AU - Chandra, Madhulika

AU - Shirani, Jamshid

AU - De Souza, Andrea Pereira

AU - Kitsis, Richard N.

AU - Russell, Robert G.

AU - Weiss, Louis M.

AU - Tang, Baiyu

AU - Jelicks, Linda A.

AU - Factor, Stephen M.

AU - Shtutin, Vitaliy

AU - Tanowitz, Herbert B.

AU - Lisanti, Michael P.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Recently, development of a caveolin-1-deficient (Cav-1 null) mouse model has allowed the detailed analysis of caveolin-1's function in the context of a whole animal. Interestingly, we now report that the hearts of Cav-1 null mice are markedly abnormal, despite the fact that caveolin-1 is not expressed in cardiac myocytes. However, caveolin-1 is abundantly expressed in the nonmyocytic cells of the heart, i.e., cardiac fibroblasts and endothelia. Quantitative imaging studies of Cav-1 null hearts demonstrate a significantly enlarged right ventricular cavity and a thickened left ventricular wall with decreased systolic function. Histological analysis reveals myocyte hypertrophy with interstitial/perivascular fibrosis. Because caveolin-1 is thought to act as a negative regulator of the p42/44 MAP kinase cascade, we performed Western blot analysis with phosphospecific antibodies that only recognize activated ERK1/2. As predicted, the p42/44 MAP kinase cascade is hyperactivated in Cav-1 null heart tissue (i.e., interstitial fibrotic lesions) and isolated cardiac fibroblasts. In addition, endothelial and inducible nitric oxide synthase levels are dramatically upregulated. Thus loss of caveolin-1 expression drives p42/44 MAP kinase activation and cardiac hypertrophy.

AB - Recently, development of a caveolin-1-deficient (Cav-1 null) mouse model has allowed the detailed analysis of caveolin-1's function in the context of a whole animal. Interestingly, we now report that the hearts of Cav-1 null mice are markedly abnormal, despite the fact that caveolin-1 is not expressed in cardiac myocytes. However, caveolin-1 is abundantly expressed in the nonmyocytic cells of the heart, i.e., cardiac fibroblasts and endothelia. Quantitative imaging studies of Cav-1 null hearts demonstrate a significantly enlarged right ventricular cavity and a thickened left ventricular wall with decreased systolic function. Histological analysis reveals myocyte hypertrophy with interstitial/perivascular fibrosis. Because caveolin-1 is thought to act as a negative regulator of the p42/44 MAP kinase cascade, we performed Western blot analysis with phosphospecific antibodies that only recognize activated ERK1/2. As predicted, the p42/44 MAP kinase cascade is hyperactivated in Cav-1 null heart tissue (i.e., interstitial fibrotic lesions) and isolated cardiac fibroblasts. In addition, endothelial and inducible nitric oxide synthase levels are dramatically upregulated. Thus loss of caveolin-1 expression drives p42/44 MAP kinase activation and cardiac hypertrophy.

KW - Cardiac fibroblasts

KW - Cardiomyopathy

KW - Caveolae

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=0037303007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037303007&partnerID=8YFLogxK

M3 - Article

C2 - 12388077

AN - SCOPUS:0037303007

VL - 284

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 2 53-2

ER -